A multi-investigator, multi-center research plan is proposed to finalize the development of gene-based retinal therapy in dog models of X-linked RP caused by mutations in RPGR prior to use in human patients. This uniformly severe, early onset human disease accounts for ~ 8-10% RP cases in North America, 15-20% in Europe, and 25% of simplex patients. The application builds on the success achieved during the current funding period which developed an AAV5-based viral vector that, together with the human IRBP promoter and human full-length RPGR cDNA, prevents the retina from degenerating in the 'slow'disease model (XLPRA1), or arrests the degeneration and maintains the photoreceptors at normal integrity in the 'fast'disease model (XLPRA2). This vector now serves as the benchmark therapeutic reagent for assessing treatment paradigms, and testing a novel therapeutic approach via the intravitreal route of delivery. The application will evaluate gene therapy in dogs having phenotypically distinct photoreceptor degenerations caused by stop or frameshift mutations in RPGRORF15, and is divided into 3 aims that will: 1-assess the long term efficacy of treatment and determine the dose-response range to establish efficacy vs toxicity dose~ 2- facilitate translational studies by targeting treatment to patient-relevant disease stage to assess treatment outcomes using criteria established during the current funding period~ 3- carry out comparative efficacy studies on modified vectors delivered via the intravitreal route that avoid secondary surgical trauma in compromised diseased photoreceptors. Four coordinated modules (M) are described that take advantage of the special expertise of each group to create a complementary and focused approach to the proposed translational studies. M1 (Large Animal experimental) will produce the dog models, and provide infrastructure resources for this work~ M2 (Large Animal Therapy) will carry out therapy studies in the canine models and develop ex vivo morphologic measures for outcome assessment~ M3 (Non-invasive Studies-Dog Models) will establish functional and structural disease features, and evaluate success of therapies using non-invasive outcome measures chosen appropriate for RPGR disease, and correlate the results with ex vivo morphologic studies~ M4 (Molecular Therapeutic Development) will provide therapeutic vectors for both subretinal and intravitreal delivery. The research studies described in this application represents a continuation of a longstanding collaboration between the module scientists that already has brought retinal gene therapy for RPE65-LCA patients to a Phase I clinical trial. The University of Pennsylvania leads this collaboration with the University of Florida.
X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene is among the most severe and common causes of inherited retinal blindness in man. To finalize the development of gene therapy for use in human patients, we will exploit viral vectors already proven effective in preventing or arresting disease in two canine models, and optimize treatments at disease stages comparable to human patients using either subretinal or intravitreal delivery routes.
|Boyd, R F; Boye, S L; Conlon, T J et al. (2016) Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs. Gene Ther 23:548-56|
|Gardiner, Kristin L; Downs, Louise; Berta-Antalics, Agnes I et al. (2016) Photoreceptor proliferation and dysregulation of cell cycle genes in early onset inherited retinal degenerations. BMC Genomics 17:221|
|Appelbaum, Tatyana; Becker, Doreen; Santana, Evelyn et al. (2016) Molecular studies of phenotype variation in canine RPGR-XLPRA1. Mol Vis 22:319-31|
|Iwabe, Simone; Ying, Gui-Shuang; Aguirre, Gustavo D et al. (2016) Assessment of visual function and retinal structure following acute light exposure in the light sensitive T4R rhodopsin mutant dog. Exp Eye Res 146:341-53|
|Downs, Louise M; Aguirre, Gustavo D (2016) FAM161A and TTC8 are Differentially Expressed in Non-Allelelic Early Onset Retinal Degeneration. Adv Exp Med Biol 854:201-7|
|Cideciyan, Artur V; Roman, Alejandro J; Jacobson, Samuel G et al. (2016) Developing an Outcome Measure With High Luminance for Optogenetics Treatment of Severe Retinal Degenerations and for Gene Therapy of Cone Diseases. Invest Ophthalmol Vis Sci 57:3211-21|
|Beltran, William A; Cideciyan, Artur V; Lewin, Alfred S et al. (2015) Gene augmentation for X-linked retinitis pigmentosa caused by mutations in RPGR. Cold Spring Harb Perspect Med 5:a017392|
|Jacobson, Samuel G; Cideciyan, Artur V; Aguirre, Gustavo D et al. (2015) Improvement in vision: a new goal for treatment of hereditary retinal degenerations. Expert Opin Orphan Drugs 3:563-575|
|Deng, Wen-Tao; Dyka, Frank M; Dinculescu, Astra et al. (2015) Stability and Safety of an AAV Vector for Treating RPGR-ORF15 X-Linked Retinitis Pigmentosa. Hum Gene Ther 26:593-602|
|Kwong, J M K; Gu, L; Nassiri, N et al. (2015) AAV-mediated and pharmacological induction of Hsp70 expression stimulates survival of retinal ganglion cells following axonal injury. Gene Ther 22:138-45|
Showing the most recent 10 out of 58 publications